Complications of COVID-19 on the Central Nervous System: Mechanisms and Potential Treatment for Easing Long COVID

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades human cells by binding to the angiotensin-converting-enzyme-2 (ACE-2) using a spike protein and leads to Coronavirus disease-2019 (COVID-19). COVID-19 primarily causes a respiratory infection that can lead to severe systemic inflammation. It is also common for some patients to develop significant neurological and psychiatric symptoms. The spread of SARS-CoV-2 to the CNS likely occurs through several pathways. Once spread in the CNS, many acute symptoms emerge, and such infections could also transpire into severe neurological complications, including encephalitis or ischemic stroke. After recovery from the acute infection, a significant percentage of patients develop "long COVID," a condition in which several symptoms of COVID-19 persist for prolonged periods. This review aims to discuss acute and chronic neurological problems after SARS-CoV-2 infection. The potential mechanisms by which SARS-CoV-2 enters the CNS and causes neuroinflammation, neuropathological changes observed in postmortem brains of COVID-19 patients, and cognitive and mood problems in COVID-19 survivors are discussed in the initial part. The later part of the review deliberates the causes of long COVID, approaches for noninvasive tracking of neuroinflammation in long COVID patients, and the potential therapeutic strategies that could ease enduring CNS symptoms observed in long COVID.

Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal

“…EMR ( 5 ) not only inhibits caspase-1 (and other caspases) but may also inhibit the activity of the main SARS-CoV-2 protease as well as SARS-CoV-2 binding to the ACE-2 receptor. Such multi-target activity may prove useful in the treatment of infections caused by positive-strand RNA viruses besides SARS-CoV-2 [ 67 , 68 ].…”

Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines

“…Клиническое разнообразие течения COVID-19 характеризовалось целым спектром неврологических нарушений, многие из которых сохранялись в течение продолжительного времени после клинического стихания инфекционного процесса. Наиболее распространенными симптомами являлись: головная боль, миалгия, потеря обоняния и вкуса, нарушение сознания, психомоторное возбуждение, вялость, явления энцефалопатия и головокружение [1840]. Сообщается, что 95,6% врачей отмечали у своих больных COVID-19 по крайней мере один из неврологический симптомов [1841].…”

Role of Microglia, Decreased Neurogenesis and Oligodendrocyte Depletion in Long COVID-Mediated Brain Impairments

“…COVID-19 is primarily characterized by an acute respiratory infection with fever, fatigue, dry cough, myalgia, and dyspnea, with less typical symptoms being headache, dizziness, and abdominal pain [ 2 ]. Current treatments involve symptomatic care with antipyretics, oxygen therapy, antiviral drugs such as interferon alpha and remdesivir, and adequate hydration [ 3 ]. A recent study found that the discharge rate of COVID-19 patients was 52%, and the fatality rate was 5% [ 4 ].…”